Otros idiomas Leo Acquisitions Corp Toronto S.E.

Acciones

LEQ.H

CA5263612098

Precio de cierre Toronto S.E. Otros sitios de cotización 00:00:00 24/11/2023			Varia. Cinco días.	Varia. 1 de enero.
0,01 ^CAD	+33,33 %		-.--%	-.--%

2021	PsyBio Therapeutics presenta ante la USPTO una patente sobre nuevas composiciones psicodélicas y métodos de tratamiento	MT
2021	PsyBio refuerza su equipo directivo con el nombramiento del Dr. Michael Spigarelli como director médico	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

PsyBio Therapeutics : Reports Second Quarter 2021 Financial Results and Provides Corporate Update on Intellectual Property and Clinical Development Milestones	30/08/21
PsyBio Therapeutics : Files Patent Application with USPTO for Production Methods of Methylated Trypatamines and Associated Analogs	16/08/21
PsyBio Therapeutics Files Patent Application with USPTO for Production Methods of Methylated Trypatamines and Associated Analogs	16/08/21
PsyBio Therapeutics : Adds NMDA Receptor Antagonists and Associated Analogues into its Intellectual Property Portfolio	04/08/21
PsyBio Therapeutics : CEO and CMO to Participate in Fireside Chat at LifeSci Partners Summer Symposium	20/07/21
PsyBio Therapeutics : Announces Uplisting to OTCQB Venture Market	14/07/21
PsyBio Therapeutics : Files Novel Psychedelic Compositions and Methods of Treatment Patent With USPTO	13/07/21
PsyBio Therapeutics : Augments Intellectual Property Portfolio with Filing of Next Novel Psychedelic Compositions and Methods of Treatment Patent	13/07/21
PsyBio Therapeutics : Announces TSXV Approval of Share Buyback Program	28/06/21
Psybio Therapeutics Corp. Initiates European Manufacturing of Proprietary Biosynthetic Psychedelic Compounds	22/06/21
PsyBio Therapeutics : Initiates European Manufacturing of Proprietary Biosynthetic Psychedelic Compounds including Psilocybin with France-based Biose Industrie	22/06/21
PsyBio Therapeutics Corp. Announces Executive Changes	01/06/21
PsyBio Therapeutics Corp.'s Board intends to launch an Equity Buyback.	01/06/21
IRW-News: PsyBio Therapeutics Corp.: PsyBio Therapeutics beruft erfahrene pharmazeutische Führungskraft Bob Oliver in sein Board of Directors	21/04/21
PsyBio Therapeutics : Appoints Pharmaceutical Veteran Bob Oliver to its Board of Directors	21/04/21
PsyBio Therapeutics : Retains KCSA Strategic Communications for Investor Relations Services	09/04/21
PsyBio Therapeutics : Strengthens Leadership Team with Appointment of Dr. Michael Spigarelli as Chief Medical Officer	05/04/21
PsyBio Therapeutics : Strengthens its Leadership Team with Appointment of Dr. Michael Spigarelli as Chief Medical Officer	05/04/21
IRW-News: PsyBio Therapeutics Corp.: PsyBio Therapeutics beginnt mit Prozessentwicklung von eigenem biosynthetischem Norbaeocystin	23/03/21
PsyBio Therapeutics Announces Retention of Market Maker	04/03/21

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Leo Acquisitions Corp Toronto S.E.

Acciones

LEQ.H

CA5263612098

Otros idiomas

Filtros